Report #2896228

Received May 12, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 17 yrs
State: KY
Recovered: Unknown
Vaccinated: Mar 19, 2026
Onset: Mar 19, 2026
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (ENGERIX-B)	GLAXOSMITHKLINE BIOLOGICALS	1	YY37B	—

Symptoms (1)

Product administered to patient of inappropriate age

Symptom narrative

Adult dose administered to 17-year-old patient; overdose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult product administered to child in a 17-year-old female patient who received HBV (Engerix B adult) (batch number YY37B, expiry date 24-AUG-2026) for prophylaxis. On 19-MAR-2026, the patient received the 1st dose of Engerix B adult. On 19-MAR-2026, an unknown time after receiving Engerix B adult, the patient experienced adult product administered to child (Verbatim: Adult dose administered to 17-year-old patient) and overdose (Verbatim: overdose). The outcome of the adult product administered to child and overdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 07-MAY-2026 Nurse reported that they had a patient who was 17 years old, received the Engerix B adult dose.